MedTrace Logo

Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections

NCT00721487 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2014-07-23

No results posted yet for this study

Summary

The primary aims of this study are to identify and characterize the immediate consequences of patients who fail fluconazole treatment during the treatment of severe infection, and to determine if fluconazole failures are more frequently associated with fluconazole-resistant or fluconazole-susceptible strains of C. albicans.

Conditions

  • Fungal Infection by Site

Interventions

DRUG

Fluconazole

Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy

Sponsors & Collaborators

  • Astellas Pharma US, Inc.

    collaborator INDUSTRY

  • CPL Associates

    lead OTHER

Principal Investigators

  • Jerome Schentag, Pharm.D. · CPL Associates, LLC

  • Joseph Paladino, Pharm.D. · CPL Associates, LLC

Eligibility

Min Age
4 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-10-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00721487 on ClinicalTrials.gov